1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Frontiers in Congenital Disorders of Glycosylation is sponsored by National Institute of Neurological Disorders and Stroke (NINDS). A collaborative project aiming to establish a nationwide network of regional centers to define the natural history, validate patient-reported outcomes, develop new diagnostic techniques, and evaluate dietary treatments for various types of congenital disorders of glycosylation.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Universities, research institutions, and healthcare organizations with expertise in metabolic disorders and clinical research. Confirm the full requirements in the official notice before applying.
Frontiers in Congenital Disorders of Glycosylation is funded by National Institute of Neurological Disorders and Stroke (NINDS). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
The AIR program is ARPA-H's most ambitious bet yet: fully autonomous robots that perform stroke-saving thrombectomies without a human surgeon. Proposals are due March 18. A strategic guide for applicants.
Read articlePAR-27-062 creates a three-year, $80,000-salary postdoctoral career award across NCI, NIAID, NIBIB, NIDCR and NINDS — and it carries a hard eligibility window that closes two years after you start your postdoc. Full analysis of the Academic Career Excellence Award, what it replaces, and why the timing rule is the whole competition.
Read articleThe HEAL Initiative's Studies to Enable Analgesic Discovery award (RFA-NS-25-023) puts federal money exactly where private capital won't go — the assay-building, screening, and hit-characterization stage of non-opioid pain therapeutics. It's a phased R61/R33, up to $350,000 in direct costs per year, with the next application deadline September 17, 2026. Here is how the two-phase structure works, who's eligible, and how to build a proposal that survives the R61-to-R33 milestone gate.
Read article